BlossomHill Q2 2026 loss, non-GAAP EPS -8.75, revenue $0, cash runway into Q2 2028
BlossomHill Therapeutics posts Q2 2026 loss with non-GAAP EPS -8.75, revenue $0, and cash runway into Q2 2028
- Q2 2026 net loss totaled $23.8 million, as disclosed in an SEC filing.
- Company completed a $168.3 million IPO during Q2 2026, as reported in the filing.
- Cash balance plus $168.3 million in IPO proceeds expected to fund operations into the second quarter of 2028.
- Company missed Q2 2026 EPS estimates but beat revenue estimates based on its reported financial results.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.